---
title: Clinical and patient-reported outcomes and neurofilament response during tofersen
  treatment in SOD1-related ALS-A multicenter observational study over 18â€‰months
date: '2024-07-20'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39031772/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240721181857&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'INTRODUCTION/AIMS: In amyotrophic lateral sclerosis (ALS) caused by
  SOD1 mutations (SOD1-ALS), tofersen received accelerated approval in the United
  States and is available via expanded access programs (EAP) outside the United States.
  This multicenter study investigates clinical and patient-reported outcomes (PRO)
  and serum neurofilament light chain (sNfL) during tofersen treatment in an EAP in
  ...'
disable_comments: true
---
INTRODUCTION/AIMS: In amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations (SOD1-ALS), tofersen received accelerated approval in the United States and is available via expanded access programs (EAP) outside the United States. This multicenter study investigates clinical and patient-reported outcomes (PRO) and serum neurofilament light chain (sNfL) during tofersen treatment in an EAP in ...